New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus
The Lupus Research Alliance welcomes new results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the...
Biogen
Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus
Decision Could Speed Up Treatment Approval for Skin-Related Lupus Manifestation The Lupus Research Alliance applauds the decision by...
Lupus Therapeutics Statement on Positive Data from Phase 3 PHOENYCS GO Trial in Moderate-To-Severe Systemic Lupus
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance (LRA), is encouraged by the positive Phase 3...
Investigational Treatment Dapirolizumab Pegol Shows Positive Results in Phase 3 Clinical Trial
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is proud to share positive topline results from...
New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus
August, 2022
We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England...
LRA Brings Encouraging News from European Rheumatology Meeting
June 2, 2022
The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS)...
Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting
November 9, 2021
Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College...
Promising News from Major Medical Meeting, EULAR
Updated June 5, 2020
One of the largest meetings for rheumatologists went virtual this year to enable scientists from around...
LRA Celebrates Major Research Breakthroughs in 2019
January 7, 2020
2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science...
Positive Study Results in Potential Treatment for Cutaneous and Systemic Lupus
December 3, 2019
The Lupus Research Alliance (LRA) is pleased to share positive results reported by Biogen Inc. from the...
Positive Early Results for BIIB059 as New Treatment Strategy
February 28, 2019
Proteins of the immune system, known as type I interferons, are responsible in part for manifestations of...